These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7512280)

  • 1. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving methotrexate/vinblastine/doxorubicin/cisplatin therapy for the treatment of transitional cell carcinoma of the urinary tract.
    Akaza H; Kotake T; Miyanaga N; Koiso K
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):70-4. PubMed ID: 7512280
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant human granulocyte colony stimulating factors: therapeutic application in the prevention of chemotherapy-induced neutropenia.
    Gabrilove JL; Jakubowski A; Scher H; Sternberg C; Wong G; Grous J; Yagoda A; Fain K; Moore MA; Clarkson B
    Behring Inst Mitt; 1988 Aug; (83):229-33. PubMed ID: 2467654
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D
    Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Scher HI
    J Urol; 1992 Nov; 148(5):1625-6. PubMed ID: 1433578
    [No Abstract]   [Full Text] [Related]  

  • 5. The application of hematopoietic growth factors in advanced transitional cell carcinoma of the urinary tract.
    de Mulder PH; Sternberg CN; van Oosterom AT; Fossa SD
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):65-9. PubMed ID: 7512278
    [No Abstract]   [Full Text] [Related]  

  • 6. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
    Noguchi S; Kubota Y; Shuin T; Masuda M; Misaki H; Yao M; Kondoh K; Sakuramoto T; Hosaka M
    Hinyokika Kiyo; 1994 Aug; 40(8):677-82. PubMed ID: 7942364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.
    Seidman AD; Scher HI; Gabrilove JL; Bajorin DF; Motzer RJ; O'Dell M; Curley T; Dershaw DD; Quinlivan S; Tao Y
    J Clin Oncol; 1993 Mar; 11(3):408-14. PubMed ID: 7680373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
    Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
    Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapy.
    Sternberg CN; Yagoda A; Scher HI; Whitmore WF; Herr HW; Morse MJ; Sogani PC; Bosl G; Watson RC; Hollander PS
    Prog Clin Biol Res; 1988; 260():551-5. PubMed ID: 3283770
    [No Abstract]   [Full Text] [Related]  

  • 10. In-vitro cell growth of human urothelial tumor cell lines under exposure with IL-3, GM-CSF, G-CSF and by combined administration with methotrexate, vinblastine, adriamycin and cisplatin.
    Block T; Treiber U; Geffken B; Vogel M; Hanauske AR; Busch R; Hartung R
    Investig Urol (Berl); 1994; 5():91-4. PubMed ID: 7536524
    [No Abstract]   [Full Text] [Related]  

  • 11. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
    J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy for non-organ confined bladder transitional cell carcinoma.
    Abi-Aad AS
    Acta Urol Belg; 1996 May; 64(2):35-7. PubMed ID: 8701808
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of recombinant human granulocyte colony stimulating factor in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum combination chemotherapy].
    Miura T; Murai T; Shimura H; Kondo I
    Hinyokika Kiyo; 1993 Mar; 39(3):209-12. PubMed ID: 7685138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract.
    Koch MO; Coussens D
    Semin Urol; 1993 Feb; 11(1):14-9. PubMed ID: 8465122
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
    Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
    Hibi H; Okamura K; Takashi M; Shimoji T; Miyake K
    Hinyokika Kiyo; 1997 Feb; 43(2):89-96. PubMed ID: 9086342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for advanced urothelial cancer.
    Yagoda A
    Semin Urol; 1983 Feb; 1(1):60-74. PubMed ID: 6382528
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status.
    Walther PJ
    Semin Urol; 1993 Nov; 11(4):227-34. PubMed ID: 8290828
    [No Abstract]   [Full Text] [Related]  

  • 20. Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients.
    Inoue T; Obara T; Saito M; Kumazawa T; Yuasa T; Matuura S; Tsuchiya N; Satoh S; Habuchi T
    Hinyokika Kiyo; 2007 Sep; 53(9):613-8. PubMed ID: 17933135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.